+ Watch VRTX
on My Watchlist
The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
This is an all or none play on their phase III Hepatitis protease inhibitor therapy - Telaprevir. If this drug comes close to expectations VRTX at below $20 is a bargain. Yes, this company has other promising drugs in the pipeline; however the value of those products is offset by the risk of competition and a fickle FDA. Therefore I focus almost exclusively on the flagship Telaprevir for success or failure of VRTX's market cap.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions